Access cutting-edge hemophilia treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.
Access hemophilia specialists in Seattle at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hemophilia treatment provided free
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study B7841005: approximately 145 adolescent and adult participants 12 to \<75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as FVIII activity \<1% or FIX activity ≤2%, respectivel
Sponsor: Pfizer
Check if you qualify for this hemophilia clinical trial in Seattle, WA
If you're searching for hemophilia treatment options in Seattle, WA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hemophilia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.